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Abstract: 
 
Background - Triadin knockout syndrome (TKOS) is a potentially lethal arrhythmia disorder 
caused by recessively inherited null variants in TRDN-encoded cardiac triadin. Despite its 
malignant phenotype, the prevalence of TKOS in sudden infant death syndrome (SIDS) and 
sudden unexplained death in the young (SUDY) is unknown.  
Methods - Exome sequencing was performed on 599 SIDS and 258 SUDY cases. Allele 
frequencies of all TRDN-null variants identified in the cardiac specific isoform of TRDN in the 
Genome Aggregation Database (gnomAD) were used to determine the estimated prevalence and 
ethnic distribution of TKOS.  
Results - No triadin null individuals were identified in 599 SIDS and 258 SUDY exomes. Using 
gnomAD, we estimate the overall prevalence of TKOS to be ~1:22.7 million individuals. 
However, TKOS prevalence is 5.5-fold higher in those of African descent (~1:4.1 million).  
Conclusions - TKOS is an exceedingly rare clinical entity that does not contribute meaningfully 
to either SIDS or SUDY. However, despite its rarity and absence in large sudden death cohorts, 
TKOS remains a malignant and potentially lethal disorder which requires further research in 
order to better care for these patients.  
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Nonstandard Abbreviations and Acronyms 
CPVT  catecholaminergic polymorphic ventricular tachycardia 
CRU  calcium release unit 
gnomAD Genome Aggregation Database 
ITKOSR International Triadin Knockout Syndrome Registry 
LoF  loss-of-function 
LQTS  long QT syndrome 
oe  observed/expected score 
pLI  probability of being loss-of-function 
RyR2  RYR2-encoded ryanodine receptor/calcium release channel 
SIDS  sudden infant death sydnrome 
SUDY  sudden unexplained death in the young 
TKOS  triadin knockout syndrome 
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Introduction 
Sudden unexplained death is defined as a sudden and unexpected death that remains unexplained 
after a thorough clinical history, death scene investigation, and postmortem examination. These 
cases can be categorized into two main groups including sudden infant death syndrome (SIDS) 
which is defined as sudden unexplained death in an infant under the age of 1 year, and accounts 
for approximately 3000 sudden deaths each year in the United States (US), and sudden 
unexplained death in the young (SUDY) which typically includes those between the ages of 1 
and 35 and occurs in up to 5000 individuals in the US each year.1 Previous studies have shown 
that ~5-10% of SIDS and ~25-30% of SUDY are caused by variants in genetic heart disease-
susceptibility genes, particularly those which underlie the channelopathies and 
cardiomyopathies. The most highly represented diseases in these studies are often long QT 
syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT).2-4   
Since 2012, mutations in TRDN-encoded cardiac triadin have been implicated as an 
underlying cause in each of these arrhythmia syndromes.5-9 Interestingly, these patients display 
clinical features of multiple arrhythmia syndromes including transient QT prolongation, 
ventricular ectopy upon stress testing, and extensive T-wave inversion in precordial leads V1-
V4. This suggests that these patients do not have typical LQTS or CPVT, but instead suffer from 
a distinct overlap disorder which is now referred to as triadin knockout syndrome (TKOS).10 
TKOS is a potentially lethal recessively inherited arrhythmia syndrome caused by 
homozygous or compound heterozygous null mutations in TRDN. Recently published data from 
the International Triadin Knockout Syndrome Registry (ITKOSR) found that 95% of TKOS 
patients are symptomatic and present at an average age of 3 years with all patients presenting by 
10 years of age. Additionally, 81% of patients have suffered at least 1 cardiac arrest and 10% 
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experienced sudden cardiac death.10  Individuals who are heterozygous for only a single TRDN 
null allele are unaffected.   
Despite its malignant and potentially lethal phenotype, the prevalence of TKOS in cases 
of sudden unexplained death remains unknown. Therefore, we sought to determine the 
prevalence of TKOS in a large multi-center molecular autopsy cohort of SIDS and SUDY cases 
as well as its prevalence and ethnic distribution in the general population.   
 
Methods 
In order to prevent the re-identification of individuals included in this study, individual patient 
data will not be made available to other researchers. This study complies with the Declaration of 
Helsinki; locally appointed ethics committees including Mayo Clinic’s Institutional Review 
Board have approved the research protocol. Data from the Genome Aggregation Database 
(gnomAD) is publically available at https://gnomad.broadinstitute.org/.11 The detailed methods 
are included in the Supplemental Material.  
 
Results 
Demographics 
We analyzed 857 sudden unexplained death cases. Of these, 599 were SIDS and 258 were 
SUDY (Table 1). Of the SIDS cases, 362 (60%) were male and 237 (40%) were female. The 
median age at death was 2 months (interquartile range (IQR) 1-4 months), and 349 (58%) of 
these cases were white. In the SUDY cohort, 176 (68%) cases were male and 82 (32%) were 
female. The median age at death was 21 years (IQR 16-29 years) with the vast majority dying 
between the ages of 1-35 years (88%), and 196 (76%) were white (Table 1).  
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Prevalence of TKOS in SIDS and SUDY 
Following next-generation sequencing and gene specific analysis of TRDN, none of the 599 
SIDS cases or 258 SUDY cases harbored either homozygous or compound heterozygous TRDN 
null variants. In fact, none of the SIDS or SUDY cases hosted even a single TRDN null allele 
(Supplemental Figure 1). We also assessed all cases for the presence of any novel homozygous 
or compound heterozygous missense variants which could potentially be disease causing, but 
none were identified. Additionally, despite the absence of TKOS in our sudden death cohorts, we 
were able to utilize an exact binomial confidence interval (CI) to calculate an upper bound of the 
frequency of TKOS in sudden death, and this was determined to be 0.43% (95% CI = 0, 0.0043).   
Estimated Prevalence and Ethnic Distribution of TKOS 
In gnomAD (n=141,456 individuals) a total of 39 loss-of-function (LoF) variants were observed 
in TRDN compared to the expected number of 50.1 LoF variants leading to a probability of being 
loss-of-function intolerant (pLI) score of 0 and an observed/expected (oe) score of 0.78 (90% CI 
= 0.6-1.02). This would indicate that TRDN is extremely tolerant of LoF variation. However, this 
is to be expected as TRDN haploinsufficient individuals do not display a disease phenotype and 
only individuals with recessively inherited homozygous/compound heterozygous null variants 
have TKOS.  
In order to estimate the prevalence of TKOS in the general population, we identified all 
cardiac specific isoform TRDN null variants present in gnomAD (Supplemental Figure 2). 
Overall, we identified only 16 unique TRDN null variants (Figure 1; Table 2). Of these, 7 (44%) 
were frameshift, 4 (25%) splice-altering, 3 (19%) nonsense, and 2 (12%) missense.  Importantly, 
none of the null variants were present as homozygous in gnomAD.  Although we are unable to 
exclude the possibility that an individual in gnomAD could be compound heterozygous for 
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TRDN null variants, individuals known to be affected by severe pediatric disease have been 
removed from the gnomAD data set making it highly unlikely that any individuals in gnomAD 
have TKOS.11 Six of the gnomAD TRDN null variants (N9fs*5, D18fs*14, T59M, W60L, 
K147*0, and Q205*) have been identified previously in cases of TKOS (Figure 1; Table 2).5-8, 
10, 12 The majority of variants (9/16; 56%) were observed only one time in gnomAD and 7 
variants (44%) were present in greater than one allele. The D18fs*14 variant was the most 
common null variant with a gnomAD allele account of 13 times in 280,480 total alleles.  The 
total allele account for all 16 identified variants was 43 (Supplemental Figure 2; Table 2). 
However, the sequencing coverage of TRDN in gnomAD is poor. In fact, only 3 of the 8 
exons (exons 1, 2, and 8) that make up the cardiac specific isoform of TRDN have greater than 
30X coverage. The other 5 exons all have coverages of ~20X or less. This causes variability in 
the number of successfully sequenced alleles at each variant location. For example, the D18fs*14 
variant was observed 13 times in 280,480 alleles, but K147fs*0 was present in 2 out of only 
89,152 alleles (Table 2). In order to correct for this suboptimal coverage and variable allele 
number across variants, we multiplied the allele frequency of each variant by the total number of 
alleles in gnomAD to generate an adjusted allele count (Supplemental Figure 2). Following 
these calculations, the estimated total adjusted allele count for the 16 TRDN null variants in 
gnomAD was 59.38 (Table 2).  
We then used the total adjusted allele count to calculate the frequency of both TRDN null 
variants and triadin null individuals in the population. By dividing the total adjusted allele count 
by the total individuals in gnomAD, we estimate that 1:2,382 individuals in gnomAD have a 
single TRDN null variant (Supplemental Figure 2; Table 3). Furthermore, by utilizing the 
Hardy-Weinberg equation, we estimate that ~1:22.7 million people in the general population 
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may have TKOS stemming from the presence of two TRDN null alleles (Supplemental Figure 
2; Table 3).  
In addition, we analyzed the prevalence of triadin null status in each of the 8 ethnic 
populations represented in gnomAD. Five of the 8 ethnic populations had a TRDN null allele 
count ≥ 1 (Table 2). The most highly represented group in gnomAD was Europeans who had an 
estimated total adjusted allele count of 34.22 and an estimated triadin null frequency of ~1:14.3 
million. The ethnicity with the highest frequency of triadin null individuals was African with a 
total adjusted allele count of 12.39 and an estimated frequency of ~1:4.1 million. Interestingly, 
all 12 unrelated African individuals in gnomAD with a TRDN null variant had the same 
D18fs*14 variant (Tables 2 and 3). Three of the populations (Ashkenazi Jewish, European 
[Finnish], and “other”) had allele counts of 0. Therefore, we were unable to determine the 
estimated frequency of triadin null individuals in these populations (Tables 2 and 3).  
 
Discussion  
TRDN-encoded cardiac triadin is a critical protein within the cardiac calcium release unit (CRU) 
complex where the L-type calcium channel is juxtaposed to the RYR2-encoded ryanodine 
receptor/calcium release channel (RyR2) on the junctional sarcoplasmic reticulum.13, 14 This 
multi-protein complex is responsible for mediating calcium sensing and proper excitation-
contraction coupling in the heart. Triadin binds to multiple proteins within the CRU including 
RyR2, calsequestrin 2, and junctin and helps mediate proper sarcoplasmic reticulum calcium 
release through RyR2, as well as stabilization of the CRU structure.14, 15  
Loss of triadin due to homozygous or compound heterozygous null mutations causes a 
distinct overlap arrhythmia disorder known as triadin knockout syndrome (TKOS).6, 10 Patients 
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with TKOS typically exhibit clinical features of multiple arrhythmia syndromes including QT 
prolongation, ventricular ectopy upon stress testing, and T-wave inversion in the precordial 
leads. TKOS also manifests with a particularly severe phenotype including sudden cardiac arrest 
at a young age, and recurrent breakthrough cardiac events despite various treatment strategies. 
Considering this unique set of features which are common among these patients, there is a strong 
likelihood that future patients who fit this phenotypic profile may have TKOS.  
Additionally, 2/21 known TKOS patients have died following sudden cardiac arrest.10 
Therefore, in this study we sought to determine the prevalence of TKOS in a large, multi-center 
cohort of sudden unexplained death cases. Interestingly, we were not able to identify any triadin 
null individuals in our 599 SIDS or 258 SUDY cases. This has led us to conclude that, despite its 
malignant and potentially lethal phenotype, TKOS does not seem to contribute meaningfully to 
either SIDS or SUDY, at least among Caucasian decedents.  
Here, we examine three viable explanations for the apparent absence of TKOS in sudden 
death involving infants, children, adolescents, and young adults. The most likely explanation for 
the absence of TKOS in our sudden death cohorts is simply the extreme rarity of the disease. 
According to our gnomAD-derived prevalence estimates, triadin null status may be as rare as 
~1:22.7 million individuals in the general population. Therefore, despite the relatively large size 
of our sudden death cohorts (compared to most molecular autopsy studies), we remain 
underpowered to capture a case of TKOS. It should be noted that these estimates are for triadin 
null individuals, and not necessarily for TKOS. While TKOS is currently thought to be 
extremely penetrant (95%)10, it remains to be seen whether mild cases will emerge as has been 
observed for most other arrhythmia syndromes.16  
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One of the main issues we encountered by using gnomAD for our prevalence estimates 
was the poor and variable sequencing coverage of TRDN which suggests that this is a difficult 
gene to sequence successfully. We were able to correct for poor coverage and generate an 
adjusted allele count for each TRDN null variant in gnomAD. However, null variants could have 
been missed in gnomAD due to poor sequencing coverage, and possibility remains that triadin 
null status, while still very rare, could be more common than our current estimates predict. 
Additionally, we recently performed whole exome sequencing and a nucleotide-level coverage 
analysis on 28 SUDY cases and their parents.17 This analysis also showed poor sequencing 
coverage of multiple exons in TRDN. Therefore, physicians and investigators should consider 
coverage when performing genetic testing or whole exome/genome sequencing on a potential 
TKOS patient as low coverage could lead disease-causing variants to be missed. 
A second potential explanation for this finding is age at death. As noted in the ITKOSR, 
all symptomatic patients presented between the ages of 1-10 years.10 In addition to SIDS being a 
highly heterogeneous disorder caused by a variety of different issues, the observation that 
patients with TKOS do not seem to present until after their first birthday may provide an 
explanation for why we did not observe any triadin null cases in our SIDS cohort. We also 
assessed the distribution of ages within our SUDY cohort and found that only 32 cases, or about 
12%, fell between the ages of 1 and 10, likely limiting our ability to capture any triadin knockout 
cases in this cohort.   
A final reason TRDN null variants may be absent from our cohorts is ethnicity. While the 
frequency of triadin null individuals in the general population is estimated to be ~1:22.7 million, 
this frequency varies greatly across the different ethnic populations in gnomAD. The population 
in which it is predicted to be the most prevalent is in those of African descent (~1:4.1 million). 
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However, when we assessed the demographics of our SUDY cohort, we found that only ~7% of 
individuals were black, again severely limiting our ability to capture a triadin null individual in 
this study.  
Interestingly, some TKOS-causative variants seem to be ethnic-specific. The most 
striking example of this is the D18fs*14-TRDN variant. Of the 13 individuals in gnomAD that 
host this variant, 12 of them are of African descent, and there are no African individuals in 
gnomAD that have any other TRDN null variants. Additionally, all of the patients in the 
ITKOSR, who have this variant, inherited it from a black parent.10 Considering the strong 
correlation of this variant to individuals of African descent, it is probable that D18fs*14 is a 
founder variant in the black population. Another example of this is Q205*-TRDN. In gnomAD, 
there are 5 individuals with this variant, and 4 of them are European. This correlates with the 
registry data where we identified 5 patients with this variant, all of whom are white/European.10  
Considering that the current world population is ~7.7 billion people, we predict based on 
gnomAD frequency that there may be 340 cases of TKOS worldwide. However, gnomAD is not 
necessarily an accurate representation of the world population, and ethnicity needs to be 
considered. In places where census data are available, such as the United States, we can utilize 
ethnic specific prevalence estimates to make these predictions. Using 2018 population estimates 
from the United States Census Bureau, we predict that there may be as many 28 cases of TKOS 
in the US. Of these, 14 would be white, 11 black, and 3 Latino. However, the number of TKOS 
cases is likely to be much higher in areas of the world where the majority of the population is 
black such as central Africa. In addition, because TKOS is a recessive disorder, we would expect 
the frequency of TKOS cases to be higher in the Middle East, South Asia, and North Africa 
where consanguineous marriages may constitute 20% to 50% of all marriages.18 Interestingly, 6 
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of the 16 families in the ITKOSR are either Indian or Arabic, and in two of these families, the 
parents are confirmed to be consanguineous first- or second-degree cousins. 
Limitations 
There are a few minor limitations to this study. First, TRDN has poor exome sequencing 
coverage across the majority of exons in gnomAD and it is possible that null variants were 
missed. Second, we are unable to determine if an individual in gnomAD is compound 
heterozygous for TRDN null variants.  However, this is unlikely due to exclusion of individuals 
with severe pediatric disease from gnomAD. Third, we only included missense variants known 
to render a null allele. Finally, while copy number variants have been shown to cause TKOS in a 
previously published patient, copy number variants were not included in our prevalence 
estimates.  
Conclusions 
Despite its rarity and absence in large sudden death cohorts, TKOS remains a malignant and 
potentially lethal disorder akin to other rare disorders such as calmodulinopathy and Timothy 
syndrome.19, 20 Not only do TKOS patients present with life-threatening cardiac events at a very 
young age, but almost 75% of patients have experienced breakthrough cardiac events while on 
conventional therapies.10 Therefore, the severe and treatment refractory nature of the disease 
highlights the urgent need for further research and development of novel treatment methods 
which are necessary in order to better care for these patients.  
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Table 1. Demographics of the SIDS and SUDY Cohorts 
 
  SIDS SUDY 
Total Cases 599 258 
Sex     
   Male 362 (60) 176 (68) 
   Female 237 (40) 82 (32) 
Age at Death     
   Average 2 (1-4) months 21 (16-29) years 
   Range 0-11 months 1-59 years 
Ethnicity     
   White 349 (58) 196 (76) 
 
*Values are n (%) or median (interquartile range) 
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Table 2. TRDN Null Variants in GnomAD and Their Corresponding Allele Counts 
  Allele Count / Adjusted Allele Count 
Triadin Null 
Variants  
(cardiac isoform) 
Total  
Allele Number All 
European  
(non-Finnish) African Latino 
Ashkenazi  
Jewish 
East  
Asian 
European  
(Finnish) 
South  
Asian Other 
c. 22+1G>T 247,980 1 / 1.14 1 / 1.15 - - - - - - - 
#c. 22+29A>G 247,606 1 / 1.14 1 / 1.15 - - - - - - - 
#p. D18fs*14 280,480 13 / 13.11 - 12 / 12.39 1 / 1.00 - - - - - 
p. K20fs*2 249,126 2 / 2.27 2 / 2.29 - - - - - - - 
#p. T59M 249,154 4 / 4.54 2 / 2.29 - 2 / 2.05 - - - - - 
#p. W60L 249,140 1 / 1.14 1 / 1.14 - - - - - - - 
c. 424+2T>C 111,664 1 / 2.53 1 / 2.68 - - - - - - - 
#p. K147*0 89,152 2 / 6.35 2 / 6.95 - - - - - - - 
c. 485-2A>G 137,668 2 / 4.11 - - - - - - 2 / 3.13 - 
p. E176fs*47 147,340 1 / 1.92 1 / 2.30 - - - - - - - 
p. L201fs*19 221,160 6 / 7.68 3 / 4.03 - 3 / 3.93 - - - - - 
#p. Q205* 163,614 5 / 8.65 4 / 7.85 - 1 / 1.46 - - - - - 
p. E221* 214,208 1 / 1.32 - - - - - - 1 / 1.10 - 
p. Q227fs*35 233,610 1 / 1.21  1 / 1.25 - - - - - - - 
p. E249fs*16 248,788 1 / 1.14 - - - - 1 / 1.11 - - - 
p. E251* 248,790 1 / 1.14 1 / 1.15 - - - - - - - 
                      
Total   43 / 59.38 20 / 34.22 12 / 12.39 7 / 8.44 - 1 / 1.11 - 3 / 4.23 - 
 
*#Indicates variants identified previously in cases of TKOS 
†Allele counts are reported as Allele Count / Adjusted Allele Count 
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Table 3. Estimated Prevalence of Triadin Null Individuals 
 
Ethnicity 
Total 
Adjusted 
Allele Count 
Total 
Individuals in 
gnomAD 
Frequency of 
Individuals with a 
TRDN Null Variant 
Frequency of 
Triadin Null 
Individuals 
All 59.38 141,456 1:2382 ~1:22.7 million 
European 
(non-
Finnish) 
34.22 64,603 1:1888 ~1:14.3 million 
African 12.39 12,487 1:1008 ~1:4.1 million 
Latino 8.44 17,720 1:2100 ~1:17.6 million 
Ashkenazi 
Jewish - 5,185 - - 
East Asian 1.11 9,977 1:8973 ~1:322.1 million 
European 
(Finnish) - 12,526 - - 
South Asian 4.23 15,308 1:3621 ~1:52.5 million 
Other - 3,614 - - 
 
 
 
 
Figure Legends: 
 
Figure 1. Cardiac triadin topology with location of triadin null variants present in gnomAD 
Depicted is a schematic representation of TRDN-encoded cardiac triadin with all 16 of the triadin 
null variants found in gnomAD. Each white dot represents the location of a corresponding null 
variant. # indicates variants identified previously in cases of TKOS. The KEKE domain is the 
region known to be responsible for the interaction and binding of both calsequestrin and the 
ryanodine receptor (amino acids 210-224). 

